Every earnings call for SPARC — management tone, guidance, KPIs and promise tracking, quarter by quarter.
SPARC · 6 transcripts · Healthcare · latest Q3 FY26Sun Pharma Advanced Research Company Limited has 6 earnings calls on record here, a Healthcare company, most recently Q3 FY26. Each quarter is scored on revenue, margins, guidance delivery and the questions management left unanswered — so the gap between what was promised and what was delivered is easy to read.
Operational Spend (Last Year) 31 million; Operational Spend (Projected) 29 million; Annual Fixed Cost Savings 10 million. Operational spend projected to decrease from $31 million last year to $29 million this year.
Read full transcript & analysisCumulative Promoter Debt 45 million_dollars; Annual Fixed Cost Savings 10 million_dollars; Projected Operational Spend 29 million_dollars. SPARC has undergone a strategic reset, narrowing therapeutic focus to oncology and immunology.
Read full transcript & analysisOpening Cash 15.2 mn USD. PROSEEK study closed at 491 patients; full analysis confirmed interim negative trends.
Read full transcript & analysisPROSEEK Trial Budget 45 million USD; PROSEEK Trial Spend 35 million USD; Current Cash Balance 20 million USD. Vodobatinib PROSEEK trial for Parkinson's Disease failed to meet primary and key secondary endpoints in interim analysis of 442 patients by March 2024.
Read full transcript & analysisPROSEEK enrollment completed in October 2023 with 513 evaluable patients globally.
Read full transcript & analysisTotal Income (FY22) ₹144 cr. Q1 FY23 Total Income was Rs.29 crores (US$3.7 million), compared to Rs.144 crores (US$19.3 million) in FY22.
Read full transcript & analysis